5 studies found for: Open Studies | marginal zone lymphoma | Phase 3
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
|3||Not yet recruiting||
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
† Study has passed its completion date and status has not been verified in more than two years.